Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review.

[1]  Leilei Jiang,et al.  A metabolomics-driven model for early remission prediction following vedolizumab treatment in patients with moderate-to-severe active ulcerative colitis. , 2024, International Immunopharmacology.

[2]  Hongxia Bao,et al.  Microbial collaborations and conflicts: unraveling interactions in the gut ecosystem , 2023, Gut microbes.

[3]  Ziyan Xu,et al.  Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds? , 2023, Frontiers in Immunology.

[4]  Ruixin Liu,et al.  Bacteroides methylmalonyl-CoA mutase produces propionate that promotes intestinal goblet cell differentiation and homeostasis. , 2023, Cell host & microbe.

[5]  Samuel J. Gavzy,et al.  Bifidobacterium mechanisms of immune modulation and tolerance , 2023, Gut microbes.

[6]  J. Söderholm,et al.  Butyrate reduces adherent-invasive E. coli-evoked disruption of epithelial mitochondrial morphology and barrier function: involvement of free fatty acid receptor 3 , 2023, Gut microbes.

[7]  Shiman Jiang,et al.  Butyrate ameliorated the intestinal barrier dysfunction and attenuated acute pancreatitis in mice fed with ketogenic diet. , 2023, Life Science.

[8]  Adrian Low,et al.  Complete genome sequences of butyrate producing Anaerostipes hadrus strains BA1 and GIF7 isolated from the terminal ileum of a healthy lean male , 2023, Microbiology Resource Announcements.

[9]  T. Hain,et al.  The microbiome landscape in pediatric Crohn’s disease and therapeutic implications , 2023, Gut microbes.

[10]  S. Paul,et al.  Candida-bacterial cross-kingdom interactions. , 2023, Trends in microbiology.

[11]  Yating Cheng,et al.  Sodium butyrate alleviates deoxynivalenol-induced porcine intestinal barrier disruption by promoting mitochondrial homeostasis via PCK2 signaling. , 2023, Journal of hazardous materials.

[12]  Nichollas E. Scott,et al.  Human gut bacteria tailor extracellular vesicle cargo for the breakdown of diet- and host-derived glycans , 2023, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Le-yang Xiang,et al.  Butyrate Protects against Clostridium difficile Infection by Regulating Bile Acid Metabolism , 2023, Microbiology spectrum.

[14]  Zhenqiang Sun,et al.  Effect of gut flora mediated‐bile acid metabolism on intestinal immune microenvironment , 2023, Immunology.

[15]  M. Simões,et al.  Quorum sensing architecture network in Escherichia coli virulence and pathogenesis. , 2023, FEMS microbiology reviews.

[16]  A. Madhavan,et al.  Harnessing the probiotic properties and immunomodulatory effects of fermented food-derived Limosilactobacillus fermentum strains: implications for environmental enteropathy , 2023, Frontiers in Nutrition.

[17]  T. Dallman,et al.  Prevalence and Persistence of Antibiotic Resistance Determinants in the Gut of Travelers Returning to the United Kingdom is Associated with Colonization by Pathogenic Escherichia coli , 2023, Microbiology spectrum.

[18]  Yuehua Wu,et al.  Bile acid metabolism and signaling: Emerging pharmacological targets of dietary polyphenols. , 2023, Pharmacology & therapeutics.

[19]  Shu Zhu,et al.  Microbial sensing in the intestine , 2023, Protein & Cell.

[20]  N. Segata,et al.  Key determinants of success in fecal microbiota transplantation: From microbiome to clinic. , 2023, Cell host & microbe.

[21]  Liangjie Hong,et al.  Artificial-enzymes-armed Bifidobacterium longum probiotics for alleviating intestinal inflammation and microbiota dysbiosis , 2023, Nature Nanotechnology.

[22]  Yong Yang,et al.  Metagenomic and targeted metabolomic analyses reveal distinct phenotypes of the gut microbiota in patients with colorectal cancer and type 2 diabetes mellitus , 2023, Chinese medical journal.

[23]  P. Halami,et al.  Lactobacillus fermentum MCC2760 abrogate high-fat induced perturbations in the enterohepatic circulation of bile acids in rats. , 2023, Life sciences.

[24]  Chun-lin Zhang,et al.  Butyrate ameliorates chronic alcoholic central nervous damage by suppressing microglia-mediated neuroinflammation and modulating the microbiome-gut-brain axis. , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[25]  S. Bhadada,et al.  A synbiotic combination of Bifidobacterium longum Bif10 and Bifidobacterium breve Bif11, isomaltooligosaccharides and finger millet arabinoxylan prevents dextran sodium sulphate induced ulcerative colitis in mice. , 2023, International journal of biological macromolecules.

[26]  Ruifu Yang,et al.  Parvimonas micra activates the Ras/ERK/c-Fos pathway by upregulating miR-218-5p to promote colorectal cancer progression , 2023, Journal of Experimental & Clinical Cancer Research.

[27]  Yizhao Tang,et al.  Gut commensal Parabacteroides distasonis alleviates inflammatory arthritis , 2023, Gut.

[28]  T. Luo,et al.  The signatures of liver metabolomics and gut microbiota in high-fat diet fed mice supplemented with rhododendrol. , 2022, Food & Function.

[29]  Ruiyue Yang,et al.  Oral Administration of Branched-Chain Amino Acids Attenuates Atherosclerosis by Inhibiting the Inflammatory Response and Regulating the Gut Microbiota in ApoE-Deficient Mice , 2022, Nutrients.

[30]  M. Garstka,et al.  Fecal microbiota transplantation enhances cell therapy in a rat model of hypoganglionosis by SCFA‐induced MEK1/2 signaling pathway , 2022, The EMBO journal.

[31]  Y. Hosomi,et al.  Cancer Cachexia among Patients with Advanced Non-Small-Cell Lung Cancer on Immunotherapy: An Observational Study with Exploratory Gut Microbiota Analysis , 2022, Cancers.

[32]  D. Figeys,et al.  Butyrate's role in human health and the current progress towards its clinical application to treat gastrointestinal disease. , 2022, Clinical nutrition.

[33]  G. D'Haens,et al.  Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance , 2022, Alimentary pharmacology & therapeutics.

[34]  Hongzhen Hu,et al.  Gut-innervating nociceptors regulate the intestinal microbiota to promote tissue protection , 2022, Cell.

[35]  P. White,et al.  Branched-chain amino acids in cardiovascular disease , 2022, Nature Reviews Cardiology.

[36]  Fen Zhang,et al.  The gut mycobiome in health, disease, and clinical applications in association with the gut bacterial microbiome assembly. , 2022, The Lancet. Microbe.

[37]  Lifen Yao,et al.  Role of gut microbiota-derived branched-chain amino acids in the pathogenesis of Parkinson’s disease: An animal study , 2022, Brain, Behavior, and Immunity.

[38]  K. Korpela,et al.  Quantitative Fecal Microbiota Profiles Relate to Therapy Response During Induction With Tumor Necrosis Factor α Antagonist Infliximab in Pediatric Inflammatory Bowel Disease , 2022, Inflammatory bowel diseases.

[39]  Mingming Sun,et al.  Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease , 2022, Frontiers in Pharmacology.

[40]  A. Ford,et al.  Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis , 2022, Gut.

[41]  W. D. de Vos,et al.  Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms , 2022, Nature Reviews Gastroenterology & Hepatology.

[42]  K. Foster,et al.  Bacterial species rarely work together , 2022, Science.

[43]  D. Rubin,et al.  Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. , 2022, The lancet. Gastroenterology & hepatology.

[44]  E. Villablanca,et al.  Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression? , 2022, Nature Reviews Gastroenterology & Hepatology.

[45]  J. Marshall,et al.  Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease , 2022, The American journal of gastroenterology.

[46]  J. S. Kim,et al.  Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases , 2022, Scientific Reports.

[47]  Jianwei Chen,et al.  Saccharina japonica fucan suppresses high fat diet-induced obesity and enriches fucoidan-degrading gut bacteria. , 2022, Carbohydrate polymers.

[48]  Philipp C. Münch,et al.  In vitro interaction network of a synthetic gut bacterial community , 2021, The ISME Journal.

[49]  Yantian Chen,et al.  CUMS and dexamethasone induce depression-like phenotypes in mice by differentially altering gut microbiota and triggering macroglia activation , 2021, General Psychiatry.

[50]  Fang Tan,et al.  Lactobacillus fermentum HFY06 attenuates D-galactose-induced oxidative stress and inflammation in male Kunming mice. , 2021, Food & function.

[51]  J. Garcia-Gil,et al.  RAID Prediction: Pilot Study of Fecal Microbial Signature With Capacity to Predict Response to Anti-TNF Treatment. , 2021, Inflammatory bowel diseases.

[52]  V. Annese,et al.  Attributes of intestinal microbiota composition and their correlation with clinical primary non-response to anti-TNF-α agents in inflammatory bowel disease patients , 2021, Bosnian journal of basic medical sciences.

[53]  Amy M. Sitapati,et al.  Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review , 2021, The American journal of gastroenterology.

[54]  M. Lukáš,et al.  Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy , 2021, Cells.

[55]  H. Matsumoto,et al.  Comparison of mucosa-associated microbiota in Crohn’s disease patients with and without anti-tumor necrosis factor-α therapy , 2021, Journal of clinical biochemistry and nutrition.

[56]  P. Sarzi-Puttini,et al.  Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis , 2021, RMD Open.

[57]  Moon S Kim,et al.  Anti‐TNFα treatment in Crohn’s disease: Impact on hepatic steatosis, gut‐derived hormones and metabolic status , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[58]  R. Leong,et al.  Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti‐TNF biological agents: real‐world registry data from the Persistence Australian National IBD Cohort (PANIC) study , 2021, Alimentary pharmacology & therapeutics.

[59]  G. Rogler,et al.  Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease. , 2021, Inflammatory bowel diseases.

[60]  M. Iborra,et al.  Evaluation of changes in intestinal microbiota in Crohn’s disease patients after anti-TNF alpha treatment , 2021, Scientific Reports.

[61]  Bangmao Wang,et al.  Maternal Emulsifier P80 Intake Induces Gut Dysbiosis in Offspring and Increases Their Susceptibility to Colitis in Adulthood , 2021, mSystems.

[62]  G. Decorti,et al.  Microbiota and Drug Response in Inflammatory Bowel Disease , 2021, Pathogens.

[63]  Yanbing Wang,et al.  The role of Short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis. , 2021, Pharmacological research.

[64]  Guangjun Yu,et al.  Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease , 2021, Gut microbes.

[65]  K. Korpela,et al.  Bacterial and fungal profiles as markers of infliximab drug response in inflammatory bowel disease. , 2020, Journal of Crohn's & colitis.

[66]  Minhu Chen,et al.  Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn's Disease. , 2020, Inflammatory bowel diseases.

[67]  J. Martiny,et al.  Alpha-, beta-, and gamma-diversity of bacteria varies across habitats , 2020, PloS one.

[68]  N. Talley,et al.  Systematic review with meta‐analysis: effectiveness of anti‐inflammatory therapy in immune checkpoint inhibitor‐induced enterocolitis , 2020, Alimentary pharmacology & therapeutics.

[69]  J. Satsangi,et al.  Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character) , 2020, Scandinavian journal of gastroenterology.

[70]  H. Tilg,et al.  Microbial butyrate synthesis indicates therapeutic efficacy of azathioprine in IBD patients. , 2020, Journal of Crohn's & colitis.

[71]  E. Elinav,et al.  High-Throughput Screen Identifies Host and Microbiota Regulators of Intestinal Barrier Function. , 2020, Gastroenterology.

[72]  M. Duplaga,et al.  Quantitative changes in selected bacteria in the stool during the treatment of Crohn's disease. , 2020, Advances in medical sciences.

[73]  D. Chang,et al.  Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle , 2020, Microorganisms.

[74]  R. Panaccione,et al.  A diversified dietary pattern is associated with a balanced gut microbial composition of Faecalibacterium and Escherichia/Shigella in patients with Crohn's disease in remission. , 2020, Journal of Crohn's & colitis.

[75]  A. Hart,et al.  Metabonomics and the gut microbiome associated with primary response to anti-TNF therapy in Crohn's disease. , 2020, Journal of Crohn's & colitis.

[76]  P. Kapusta,et al.  Changes in the Intestinal Microbiota Are Seen Following Treatment with Infliximab in Children with Crohn’s Disease , 2020, Journal of clinical medicine.

[77]  M. Gazouli,et al.  The Interplay between Mucosal Microbiota Composition and Host Gene-Expression is Linked with Infliximab Response in Inflammatory Bowel Diseases , 2020, Microorganisms.

[78]  H. Sokol,et al.  Gut microbiota-derived metabolites as key actors in inflammatory bowel disease , 2020, Nature Reviews Gastroenterology & Hepatology.

[79]  M. Fischbach,et al.  Dysbiosis-Induced Secondary Bile Acid Deficiency Promotes Intestinal Inflammation. , 2020, Cell host & microbe.

[80]  M. Murad,et al.  First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. , 2020, Clinical Gastroenterology and Hepatology.

[81]  C. Benoist,et al.  Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis , 2019, Nature.

[82]  M. Bramuzzo,et al.  Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients , 2019, Clinical and translational science.

[83]  A. Levine,et al.  Decreased enteric bacterial composition and diversity in South American Crohn's disease vary with the choice of treatment strategy and time since diagnosis. , 2019, Journal of Crohn's & colitis.

[84]  K. Ding,et al.  An orally administered butyrate-releasing xylan derivative reduces inflammation in dextran sulphate sodium-induced murine colitis. , 2019, International journal of biological macromolecules.

[85]  J. Raes,et al.  Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients with Inflammatory Bowel Diseases. , 2019, Gastroenterology.

[86]  Minhu Chen,et al.  Systematic Review and Meta-analysis: Short-Chain Fatty Acid Characterization in Patients With Inflammatory Bowel Disease. , 2019, Inflammatory bowel diseases.

[87]  M. Morino,et al.  Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease , 2019, Journal of clinical medicine.

[88]  D. Plichta,et al.  Therapeutic Opportunities in Inflammatory Bowel Disease: Mechanistic Dissection of Host-Microbiome Relationships , 2019, Cell.

[89]  E. Alyamani,et al.  Microbial dysbiosis in inflammatory bowel diseases: results of a metagenomic study in Saudi Arabia. , 2019, Minerva gastroenterologica e dietologica.

[90]  B. Henrissat,et al.  Bacteroidetes use thousands of enzyme combinations to break down glycans , 2019, Nature Communications.

[91]  Kevin S. Bonham,et al.  Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases , 2019, Nature.

[92]  Kiuk Lee,et al.  Lactobacillus fermentum species ameliorate dextran sulfate sodium-induced colitis by regulating the immune response and altering gut microbiota , 2019, Gut microbes.

[93]  M. Schirmer,et al.  Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study , 2019, The Lancet.

[94]  J. Stelling,et al.  Microbial network disturbances in relapsing refractory Crohn’s disease , 2019, Nature Medicine.

[95]  S. Shen-Orr,et al.  Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response , 2019, Nature Communications.

[96]  W. Garrett,et al.  Fusobacterium nucleatum — symbiont, opportunist and oncobacterium , 2018, Nature Reviews Microbiology.

[97]  C. Huttenhower,et al.  Gut microbiome structure and metabolic activity in inflammatory bowel disease , 2018, Nature Microbiology.

[98]  Bangmao Wang,et al.  Maternal High Fat Diet Alters Gut Microbiota of Offspring and Exacerbates DSS-Induced Colitis in Adulthood , 2018, Front. Immunol..

[99]  B. Helmink,et al.  Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis , 2018, Nature Medicine.

[100]  P. Vandenabeele,et al.  Glucocorticoid receptor dimers control intestinal STAT1 and TNF-induced inflammation in mice , 2018, The Journal of clinical investigation.

[101]  H. Huynh,et al.  Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn’s disease? , 2018, Annals of gastroenterology.

[102]  Xi Ma,et al.  Branched Chain Amino Acids: Beyond Nutrition Metabolism , 2018, International journal of molecular sciences.

[103]  P. Schloss,et al.  Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn’s Disease Patients , 2018, mBio.

[104]  Guangjun Yu,et al.  Characteristics of Faecal Microbiota in Paediatric Crohn’s Disease and Their Dynamic Changes During Infliximab Therapy , 2018, Journal of Crohn's & colitis.

[105]  Amnon Amir,et al.  Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction , 2018, mSystems.

[106]  L. Albenberg,et al.  Gut microbiota and IBD: causation or correlation? , 2017, Nature Reviews Gastroenterology &Hepatology.

[107]  Naglaa F. Khedr,et al.  Branched chain amino acids supplementation modulates TGF‐β1/Smad signaling pathway and interleukins in CCl4‐induced liver fibrosis , 2017, Fundamental & clinical pharmacology.

[108]  Siddharth Singh,et al.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. , 2017, Gastroenterology.

[109]  H. Paik,et al.  Anti-inflammatory and anti-genotoxic activity of branched chain amino acids (BCAA) in lipopolysaccharide (LPS) stimulated RAW 264.7 macrophages , 2017, Food Science and Biotechnology.

[110]  Ashwin N Ananthakrishnan,et al.  Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. , 2017, Cell host & microbe.

[111]  S. Keely,et al.  Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. , 2017, American journal of physiology. Gastrointestinal and liver physiology.

[112]  Ian D. Wilson,et al.  Gut microbiota modulation of chemotherapy efficacy and toxicity , 2017, Nature Reviews Gastroenterology &Hepatology.

[113]  Harry Sokol,et al.  A microbial signature for Crohn's disease , 2017, Gut.

[114]  J. Satsangi,et al.  Biomarkers in Search of Precision Medicine in IBD , 2016, The American Journal of Gastroenterology.

[115]  A. Zarzuelo,et al.  The glucocorticoid budesonide has protective and deleterious effects in experimental colitis in mice. , 2016, Biochemical pharmacology.

[116]  L. Öhman,et al.  Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition. , 2016, Journal of Crohn's & colitis.

[117]  D. Aguirre de Cárcer,et al.  Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism , 2016, Gut.

[118]  T. Vatanen,et al.  Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease , 2016, Genome Medicine.

[119]  Hanns-Ulrich Marschall,et al.  Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. , 2016, Cell metabolism.

[120]  S. Umar,et al.  Microbiome, Metabolome and Inflammatory Bowel Disease , 2016, Microorganisms.

[121]  R. Eliakim,et al.  Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[122]  R. Słomski,et al.  The impact of genetic factors on response to glucocorticoids therapy in IBD , 2016, Scandinavian journal of gastroenterology.

[123]  Makoto Fujii,et al.  Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease , 2016, Digestion.

[124]  I. Amit,et al.  Microbiota-Modulated Metabolites Shape the Intestinal Microenvironment by Regulating NLRP6 Inflammasome Signaling , 2015, Cell.

[125]  G. Kaplan,et al.  The global burden of IBD: from 2015 to 2025 , 2015, Nature Reviews Gastroenterology &Hepatology.

[126]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[127]  Eric Z. Chen,et al.  Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn's Disease. , 2015, Cell host & microbe.

[128]  J. Garcia-Gil,et al.  Anti-tumour Necrosis Factor Treatment with Adalimumab Induces Changes in the Microbiota of Crohn's Disease. , 2015, Journal of Crohn's & Colitis.

[129]  E. Zoetendal,et al.  Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation , 2015, The American Journal of Gastroenterology.

[130]  A. Hart,et al.  Environmental Factors in the Relapse and Recurrence of Inflammatory Bowel Disease: A Review of the Literature , 2015, Digestive Diseases and Sciences.

[131]  A. Gasbarrini,et al.  Tu1302 Anti-TNF-α Induction Regimen Modulates Gut Microbiota Molecular Composition While Inducing Clinical Response in Crohn's Disease Patients: Toward a Personalized Medicine , 2015 .

[132]  Ashwin N. Ananthakrishnan,et al.  Epidemiology and risk factors for IBD , 2015, Nature Reviews Gastroenterology &Hepatology.

[133]  G. Fiorino,et al.  Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. , 2015, Immunotherapy.

[134]  M. V. Vander Heiden,et al.  Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. , 2015, Cancer research.

[135]  Dan Knights,et al.  Complex host genetics influence the microbiome in inflammatory bowel disease , 2014, Genome Medicine.

[136]  D. Pal,et al.  Anticancer, Anti-Inflammatory, and Analgesic Activities of Synthesized 2-(Substituted phenoxy) Acetamide Derivatives , 2014, BioMed research international.

[137]  E. Louis,et al.  Alterations in the Intestinal Microbiome (Dysbiosis) as a Predictor of Relapse After Infliximab Withdrawal in Crohn's Disease , 2014, Inflammatory bowel diseases.

[138]  M. Savageau,et al.  Relative Amino Acid Composition Signatures of Organisms and Environments , 2013, PloS one.

[139]  Jan Verhaegen,et al.  A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis , 2013, Gut.

[140]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[141]  H. Flint,et al.  Pro-Inflammatory Flagellin Proteins of Prevalent Motile Commensal Bacteria Are Variably Abundant in the Intestinal Microbiome of Elderly Humans , 2013, PloS one.

[142]  H. Sokol,et al.  Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases , 2012, Gut.

[143]  Richard Hansen,et al.  IBD—what role do Proteobacteria play? , 2012, Nature Reviews Gastroenterology &Hepatology.

[144]  R. Meli,et al.  Potential beneficial effects of butyrate in intestinal and extraintestinal diseases , 2011 .

[145]  O. Inatomi,et al.  Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysis , 2011, Journal of Gastroenterology.

[146]  Frans Schuit,et al.  Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway* , 2010, Inflammatory bowel diseases.

[147]  D. Haller,et al.  Isolation of bacteria from mouse caecal samples and description of Bacteroides sartorii sp. nov , 2010, Archives of Microbiology.

[148]  Yoshio Araki,et al.  Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. , 2004, International journal of molecular medicine.

[149]  J. Brosnan.  Interorgan amino acid transport and its regulation. , 2003, The Journal of nutrition.

[150]  L. Yin,et al.  The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. , 2000, Gastroenterology.

[151]  S. Akiyama,et al.  Integrins in cell adhesion and signaling. , 1996, Human cell.

[152]  L. Picker,et al.  Lymphocyte Homing and Homeostasis , 1996, Science.

[153]  Xiaoying Bian,et al.  Recombineering-Mediated Genome Editing in Burkholderiales Strains. , 2022, Methods in molecular biology.

[154]  Xin Lu,et al.  Chronic glucocorticoid treatment induced circadian clock disorder leads to lipid metabolism and gut microbiota alterations in rats , 2018, Life sciences.

[155]  P. Rutgeerts,et al.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.

[156]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[157]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.